By Alex Meola, Scientist II, Homology Medicines
Speed to the clinic and patient safety are important goals when working to bring novel genetic therapies to patients. To achieve these goals, Homology Medicines decided to invest in internal development and manufacturing operations not long after the Company’s founding, which included the construction of a 25,000 sq ft GMP manufacturing facility adjacent to its headquarters. This allowed for efficient collaboration, integration, and iteration as Homology developed a commercial platform process that supports both gene therapy and gene editing constructs. By focusing on early product engagement with research, a dedicated process development team, and a collaborative feedback loop with its internal manufacturing facility, Homology established the perfect trifecta for rapid learning.